A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Postmenopausal women will receive testosterone gel or matching placebo gel daily. Sebum excretion rates will be measured before and after 6 weeks of treatment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• Subject is at least 3 years postmenopausal

• Subject is in good general health

• Subject is willing to avoid excess alcohol or strenuous physical activity during the study

Exclusion Criteria:

• Subject has donated a unit of blood or has taken an investigational drug in another clinical trial in the last 4 weeks

• Subject is a regular user of any illicit drugs

• Subject drinks excessive amounts of coffee, tea or cola

• Subject has used an estrogen or progestogens hormone replacement therapy in the past 6 months

• Subject has a history of cancer

• Subject has acne